The p75NTR neurotrophin receptor is a tumor suppressor in human and murine retinoblastoma development

International Journal of Cancer

Volumn 122, Issue 9, 2008, Pages 2023-2029

  Dimaras, Helen ^a,b,c   Gallie, Brenda L ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Apoptosis; p75NTR; Retinoblastoma; Tumor development; Tumor suppressor gene

Indexed keywords

ADENOVIRUS VECTOR; NEUROTROPHIN RECEPTOR; NEUROTROPHIN RECEPTOR P75; CASPASE 3; NERVE GROWTH FACTOR RECEPTOR; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; COMPARATIVE STUDY; CONTROLLED STUDY; EXON; EXPRESSION VECTOR; HETEROZYGOTE; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; RETINA; RETINOBLASTOMA; TUMOR SUPPRESSOR GENE; ADENOVIRUS; ANIMAL; CELL TRANSFORMATION; ENZYME ACTIVATION; EXPERIMENTAL NEOPLASM; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE; RETINA TUMOR; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; ENZYME ACTIVATION; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; NEOPLASMS, EXPERIMENTAL; RECEPTOR, NERVE GROWTH FACTOR; RETINAL NEOPLASMS; RETINOBLASTOMA; TUMOR SUPPRESSOR PROTEINS;

EID: 40749133036     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23356     Document Type: Article

References (43)

1. Gallie BL, Campbell C, Devlin H, Duckett A, Squire JA. Developmental basis of retinal-specific induction of cancer by RB mutation. Cancer Res 1999;59(7 Suppl):1731s-1735s.
2. Marchong MN, Chen D, Corson TW, Lee C, Harmandayan M, Bowles E, Chen N, Gallie BL. Minimal 16q genomic loss implicates cadherin-11 in retinoblastoma. Mol Cancer Res 2004;2:495-503.
3. Corson TW, Huang A, Tsao MS, Gallie BL. KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. Oncogene 2005;24:4741-53.
4. Orlic M, Spencer CE, Wang L, Gallie BL. Expression analysis of 6p22 genomic gain in retinoblastoma. Genes Chromosomes Cancer 2006;45:72-82.
5. Dimaras H, Coburn B, Pajovic S, Gallie BL. The loss of p75 neurotrophin receptor expression accompanies malignant progression to human and murine retinoblastoma. Mol Carcinog 2006;45:333-43.
6. Bowles E, Corson TW, Bayani J, Squire JA, Wong N, Lai PB, Gallie BL. Profiling genomic copy number changes in retinoblastoma beyond loss of RB1. Genes Chromosomes Cancer 2007;46:118-29.
7. Dimaras H, Halliday W, Orlic M, Khetan V, Gallie B. The molecular characterization of retinoma. Presented at the 15th international society for genetic eye disease and 12th international retinoblastoma symposium, Whistler BC, Canada, 2005.
8. Richter S, Vandezande K, Chen N, Zhang K, Sutherland J, Anderson J, Han L, Panton R, Branco P, Gallie B. Sensitive and efficient detection of RB1 gene mutations enhances care for families with retinoblastoma. Am J Hum Genet 2003;72:253-69.
9. Kimura N, Nakamura M, Kimura I, Nagura H. Tissue localization of nerve growth factor receptors: trk A and low-affinity nerve growth factor receptor in neuroblastoma, pheochromocytoma, and retinoblastoma. Endocr Pathol 1996;7:281-9.
10. Roux PP, Barker PA. Neurotrophin signaling through the p75 neurotrophin receptor. Prog Neurobiol 2002;67:203-33.
11. Ding J, Hu B, Tang LS, Yip HK. Study of the role of the low-affinity neurotrophin receptor p75 in naturally occurring cell death during development of the rat retina. Dev Neurosci 2001;23:390-8.
12. Frade JM, Barde YA. Genetic evidence for cell death mediated by nerve growth factor and the neurotrophin receptor p75 in the developing mouse retina and spinal cord. Development 1999;126:683-90.
13. Frade JM, Rodriguez-Tebar A, Barde YA. Induction of cell death by endogenous nerve growth factor through its p75 receptor. Nature 1996;383:166-8.
14. Windle JJ, Albert DM, O'Brien JM, Marcus DM, Disteche CM, Bernards R, Mellon PL. Retinoblastoma in transgenic mice. Nature 1990;343:665-9.
15. Lee KF, Li E, Huber LJ, Landis SC, Sharpe AH, Chao MV, Jaenisch R. Targeted mutation of the gene encoding the low affinity NGF receptor p75 leads to deficits in the peripheral sensory nervous system. Cell 1992;69:737-49.
16. Peterson DA, Dickinson-Anson HA, Leppert JT, Lee KF, Gage FH. Central neuronal loss and behavioral impairment in mice lacking neurotrophin receptor p75. J Comp Neurol 1999;404:1-20.
17. von Schack D, Casademunt E, Schweigreiter R, Meyer M, Bibel M, Dechant G. Complete ablation of the neurotrophin receptor p75NTR causes defects both in the nervous and the vascular system. Nat Neurosci 2001;4:977-8.
18. Paul CE, Vereker E, Dickson KM, Barker PA. A pro-apoptotic fragment of the p75 neurotrophin receptor is expressed in p75NTR ExonIV null mice. J Neurosci 2004;24:1917-23.
19. McFall RC, Sery TW, Makadon M. Characterization of a new continuous cell line derived from a human retinoblastoma. Cancer Res 1977;37:1003-10.
20. Reid TW, Albert DM, Rabson AS, Russell P, Craft J, Chu EW, Tralka TS, Wilcox JL. Characteristics of an established cell line of retinoblastoma. J Natl Cancer Inst 1974;53:347-60.
21. Bhakar AL, Howell JL, Paul CE, Salehi AH, Becker EB, Said F, Bonni A, Barker PA. Apoptosis induced by p75NTR overexpression requires Jun kinase-dependent phosphorylation of Bad. J Neurosci 2003;23:11373-81.
22. Chen D, Livne-bar I, Vanderluit JL, Slack RS, Agochiya M, Bremner R. Cell-specific effects of RB or RB/p107 loss on retinal development implicate an intrinsically death-resistant cell-of-origin in retinoblastoma. Cancer Cell 2004;5:539-51.
23. MacPherson D, Sage J, Kim T, Ho D, McLaughlin ME, Jacks T. Cell type-specific effects of Rb deletion in the murine retina. Genes Dev 2004;18:1681-94.
24. Zhang J, Schweers B, Dyer MA. The first knockout mouse model of retinoblastoma. Cell Cycle 2004;3:952-9.
25. Robanus-Maandag E, Dekker M, van der Valk M, Carrozza ML, Jeanny JC, Dannenberg JH, Berns A, te Riele H. p107 is a suppressor of retinoblastoma development in pRb-deficient mice. Genes Dev 1998;12:1599-609.
26. Macpherson D, Conkrite K, Tam M, Mukai S, Mu D, Jacks T. Murine bilateral retinoblastoma exhibiting rapid-onset, metastatic progression and N-myc gene amplification. EMBO J 2007;26:784-94.
27. Hahn WC, Dessain SK, Brooks MW, King JE, Elenbaas B, Sabatini DM, DeCaprio JA, Weinberg RA. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol 2002;22:2111-23.
28. Arevalo JC, Wu SH. Neurotrophin signaling: many exciting surprises! Cell Mol Life Sci 2006;63:1523-37.
29. al-Ubaidi MR, Font RL, Quiambao AB, Keener MJ, Liou GI, Overbeek PA, Baehr W. Bilateral retinal and brain tumors in transgenic mice expressing simian virus 40 large T antigen under control of the human interphotoreceptor retinoid-binding protein promoter. J Cell Biol 1992;119:1681-7.
30. Griep AE, Krawcek J, Lee D, Liem A, Albert DM, Carabeo R, Drinkwater N, McCall M, Sattler C, Lasudry JG, Lambert PF. Multiple genetic loci modify risk for retinoblastoma in transgenic mice. Invest Ophthalmol Vis Sci 1998;39:2723-32.
31. Van Quill KR, Dioguardi PK, Tong CT, Gilbert JA, Aaberg TM, Jr, Grossniklaus HE, Edelhauser HF, O'Brien JM. Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma. Ophthalmology 2005;112:1151-8.
32. Dawson DG, Gleiser J, Zimbric ML, Darjatmoko SR, Lindstrom MJ, Strugnell SA, Albert DM. Toxicity and dose-response studies of 1-alpha hydroxyvitamin D2 in LH-β-tag transgenic mice. Ophthalmology 2003;110:835-9.
33. Murray TG, Cicciarelli N, O'Brien JM, Hernandez E, Mueller RL, Smith BJ, Feuer W. Subconjunctival carboplatin therapy and cryotherapy in the treatment of transgenic murine retinoblastoma. Arch Ophthalmol 1997;115:1286-90.
34. Grasemann C, Gratias S, Stephan H, Schuler A, Schramm A, Klein-Hitpass L, Rieder H, Schneider S, Kappes F, Eggert A, Lohmann DR. Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma. Oncogene 2005;24:6441-9.
35. Paderova J, Orlic-Milacic M, Yoshimoto M, Santos GdC, Gallie B, Squire J. Novel 6p rearrangements and recurrent translocation breakpoints in retinoblastoma cell lines identified by spectral karyotyping and mBAND analyses. Cancer Genet Cytogenet 2007;179:102-11.
36. Rodriguez-Tebar A, Dechant G, Barde YA. Binding of brain-derived neurotrophic factor to the nerve growth factor receptor. Neuron 1990;4:487-92.
37. Frade JM, Barde YA. Nerve growth factor: two receptors, multiple functions. Bioessays 1998;20:137-45.
38. Ryden M, Murray-Rust J, Glass D, Ilag LL, Trupp M, Yancopoulos GD, McDonald NQ, Ibanez CF. Functional analysis of mutant neurotrophins deficient in low-affinity binding reveals a role for p75LNGFR in NT-4 signalling. EMBO J 1995;14:1979-90.
39. Lee R, Kermani P, Teng KK, Hempstead BL. Regulation of cell survival by secreted proneurotrophins. Science 2001;294:1945-8.
40. Nykjaer A, Lee R, Teng KK, Jansen P, Madsen P, Nielsen MS, Jacobsen C, Kliemannel M, Schwarz E, Willnow TE, Hempstead BL, Petersen CM. Sortilin is essential for proNGF-induced neuronal cell death. Nature 2004;427:843-8.
41. Majdan M, Miller FD. Neuronal life and death decisions functional antagonism between the Trk and p75 neurotrophin receptors. Int J Dev Neurosci 1999;17:153-61.
42. Johnston AL, Lun X, Rahn JJ, Liacini A, Wang L, Hamilton MG, Parney IF, Hempstead BL, Robbins SM, Forsyth PA, Senger DL. The p75 neurotrophin receptor is a central regulator of glioma invasion. PLoS Biol 2007;5:e212.
43. Allen J, Khwaja F, Djakiew D. Gene therapy of prostate xenograft tumors with a p75NTR lipoplex. Anticancer Res 2004;24:2997-3003.